All times are listed in CEST (Central European Summer Time)

Displaying One Session

ESMO Colloquium
Date
23.09.2020
Chairs
  • Myung-Ju Ahn (Seoul, Korea, Republic of)
  • Martin Reck (Grosshansdorf, Germany)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

Is a combination of anti-angiogenic with EFGR TKI a new standard

ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

Do immune check point work in EGFR TKI?

ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium